Point-of-care testing for procalcitonin in identifying bacterial infections in young infants: a diagnostic accuracy study

Thomas Waterfield, Julie-Ann Maney, Martin Hanna, Derek Fairley, Michael D Shields, Thomas Waterfield, Julie-Ann Maney, Martin Hanna, Derek Fairley, Michael D Shields

Abstract

Background: The primary objective of this study was to report on the diagnostic accuracy of point-of-care testing (POCT) for procalcitonin (PCT) in identifying invasive bacterial infections in young infants. Invasive bacterial infection was defined as the isolation of a bacterial pathogen in blood or cerebrospinal fluid culture.

Methods: This was a prospective observational diagnostic accuracy study. Young infants less than 90 days of age presenting to the Royal Belfast Hospital for Sick Children with signs of possible bacterial infection were eligible for inclusion. Eligible infants underwent point-of-care testing for procalcitonin in the emergency department. Testing was performed by clinical staff using 0.5 ml of whole blood. Results were available within 20 min.

Results: 126 children were included over a 5-month period between September 2017 and January 2018. There were 14 children diagnosed with bacterial infections (11.1%). Of these 4 children were diagnosed with invasive bacterial infections (3.2%). POCT procalcitonin demonstrated an excellent diagnostic accuracy for identifying children with invasive bacterial infection area under the curve (AUC) of 0.97(95% CI, 0.94 to 1.0). At a cut-off value of 1.0 ng/ml is highly accurate at identifying infants at risk of invasive bacterial infection with a sensitivity and specificity of 1.00 and 0.92 respectively.

Conclusions: Point-of-care procalcitonin can be performed quickly in the emergency department and demonstrates an excellent diagnostic accuracy for the identification of young infants with invasive bacterial infections.

Trial registration: NCT03509727 Retrospectively registered on 26th April 2018.

Keywords: Biomarker; Febrile; Infant; Infection; PCT; Pediatrics; Procalcitonin; Sepsis.

Conflict of interest statement

Ethics approval and consent to participate

This service development project was reviewed and approved by the Belfast Health and Social Care Trust Research and Development office and no Office for Research Ethics Committees approval was deemed necessary.

Consent for publication

Not applicable.

Competing interests

Dr. Waterfield has received an honorarium from Thermofischer for teaching at an educational seminar.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow Diagram of Study
Fig. 2
Fig. 2
Receiver Operating Characteristic (ROC) Curves for Procalcitonin (PCT)

References

    1. National Institute for Health and Care Excellence (NCIE): Fever in under 5s: assessment and initial management. . Accessed 13 Nov 2017.
    1. Jaskiewicz JA, McCarthy CA, Richardson AC, et al. Febrile infants at low risk for serious bacterial infection--an appraisal of the Rochester criteria and implications for management. Febrile Infant Collaborative Study Group. Pediatrics. 1994;94:390–396.
    1. Baker MD, Bell LM, Avner JR. Outpatient management without antibiotics of fever in selected infants. N Engl J Med. 1993;329:1437–1441. doi: 10.1056/NEJM199311113292001.
    1. Baskin MN, O’Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. J Pediatr. 1992;120:22–27. doi: 10.1016/S0022-3476(05)80591-8.
    1. Gomez B, Mintegi S, Bressan S, et al. Validation of the “step-by-step” approach in the Management of Young Febrile Infants. Pediatrics. 10.1542/peds.2015-4381.
    1. Verbakel JY, Lemiengre MB, De Burghgraeve T, et al. Point-of-care C reactive protein to identify serious infection in acutely ill children presenting to hospital: prospective cohort study. Arch Dis Child. 2017. 10.1136/archdischild-2016-312384.
    1. Downes KJ, Weiss SL, Gerber JS, et al. A pragmatic biomarker-driven algorithm to guide antibiotic use in the pediatric intensive care unit: the optimizing antibiotic strategies in sepsis (OASIS) study. J Pediatric Infect Dis Soc. 2017;6:134–141.
    1. Nath SR, Jayapalan S, Nair H, et al. Comparative diagnostic test evaluation of serum procalcitonin and C-reactive protein in suspected bloodstream infections in children with cancer. J Med Microbiol. 2017;66:622–627. doi: 10.1099/jmm.0.000478.
    1. Carrol ED, Newland P, Thomson APJ, et al. Prognostic value of procalcitonin in children with meningococcal sepsis. Crit Care Med. 2005;33:224–225. doi: 10.1097/.
    1. Bolia R, Srivastava A, Marak R. Role of Procalcitonin and C-Reactive Protein as Biomarkers of Infection in Children with Liver Disease. J Pediatr Gastroenterol Nutr. 2016. 10.1097/MPG.0000000000001181.
    1. Bertolus C, Schouman T, Aubry A, et al. Is procalcitonin a useful biomarker for the risk stratification of facial cellulitis? J Cranio-Maxillofacial Surg. 2016;44:995–997. doi: 10.1016/j.jcms.2016.05.023.
    1. Li X, Wang X, Li S, et al. Diagnostic value of procalcitonin on early postoperative infection after pediatric cardiac surgery. Pediatr Crit Care Med. 2017;18:420–428. doi: 10.1097/PCC.0000000000001118.
    1. Stocker M, van Herk W, el Helou S et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). . 2017. doi: 10.1016/S0140-6736(17)31444-7.
    1. Milcent K, Faesch S, Gras-Le Guen C, et al. Use of Procalcitonin assays to predict serious bacterial infection in young febrile infants. JAMA Pediatr. 2016;170:62. doi: 10.1001/jamapediatrics.2015.3210.
    1. Alcoba G, Manzano S, Lacroix L, et al. Proadrenomedullin and copeptin in pediatric pneumonia: a prospective diagnostic accuracy study. BMC Infect Dis. 2015;15:347. doi: 10.1186/s12879-015-1095-5.
    1. Gomez B, Bressan S, Mintegi S, et al. Diagnostic value of Procalcitonin in well-appearing young febrile infants. Pediatrics. 2012;130:815. doi: 10.1542/peds.2011-3575.
    1. Mintegi S, Bressan S, Gomez B, et al. Accuracy of a sequential approach to identify young febrile infants at low risk for invasive bacterial infection. Emerg Med J. 2014. 10.1136/emermed-2013-202449.
    1. Mintegi S, Gomez B, Carro A, et al. Invasive bacterial infections in young afebrile infants with a history of fever. Arch Dis Child. 2018;103(7):665–669.
    1. Chauhan N, Tiwari S, Jain U. Potential biomarkers for effective screening of neonatal sepsis infections: an overview. Microb Pathog. 2017;107:234–242. doi: 10.1016/j.micpath.2017.03.042.
    1. Jain S, Cheng J, Alpern ER, et al. Management of Febrile Neonates in US pediatric emergency departments. Pediatrics. 2014;133(2):187–195. doi: 10.1542/peds.2013-1820.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe